Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism.

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol (2013) 1.69

Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs (2013) 1.49

Direct oral anticoagulants: integration into clinical practice. Postgrad Med J (2014) 1.40

The pharmacological landscape and therapeutic potential of serine hydrolases. Nat Rev Drug Discov (2012) 1.39

Laboratory assessment of rivaroxaban: a review. Thromb J (2013) 1.16

Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol (2013) 0.98

Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. J Thromb Haemost (2014) 0.95

The evolution of anticoagulant therapy. Blood Transfus (2015) 0.86

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet (2016) 0.85

Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. Int J Gen Med (2013) 0.83

Alternative to oral dicoumarin anticoagulants: Considerations in dental care. J Clin Exp Dent (2013) 0.82

Anticoagulant therapy for patients with ischaemic stroke. Nat Rev Neurol (2012) 0.82

Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J (2014) 0.81

Rivaroxaban for the treatment of pulmonary embolism. Adv Ther (2013) 0.81

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. Vasc Health Risk Manag (2013) 0.81

Novel oral anticoagulants and the 73rd anniversary of historical warfarin. J Saudi Heart Assoc (2015) 0.78

Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions. J Am Heart Assoc (2016) 0.78

Dental management of patients receiving anticoagulant and/or antiplatelet treatment. J Clin Exp Dent (2014) 0.77

Evaluation of the vascular protective effects of new oral anticoagulants in high-risk patients with atrial fibrillation (PREFER-AF): study protocol for a randomized controlled trial. Trials (2016) 0.77

Direct thrombin inhibitors in cardiovascular disease. Nat Rev Cardiol (2012) 0.77

Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. Vasc Health Risk Manag (2015) 0.77

Real-world data confirm clinical trial outcomes for rivaroxaban in orthopaedic patients. Curr Orthop Pract (2015) 0.76

Nucleic Acid Aptamers: An Emerging Tool for Biotechnology and Biomedical Sensing. Sensors (Basel) (2015) 0.76

Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants. Int J Gen Med (2016) 0.75

Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. Clin Cardiol (2016) 0.75

Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase. PLoS One (2016) 0.75

SARConnect: A Tool to Interrogate the Connectivity Between Proteins, Chemical Structures and Activity Data. Mol Inform (2012) 0.75

Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice. Vasc Health Risk Manag (2014) 0.75

[Prevention of venous thromboembolism in musculoskeletal surgery]. Wien Klin Wochenschr (2014) 0.75

Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med (2012) 6.42

Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05

Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet (2010) 5.30

Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73

Cardiovascular safety of rofecoxib (Vioxx): lessons learned and unanswered questions: we need processes in place to follow up suspicions about serious adverse events. Med J Aust (2004) 3.34

Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16

Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 3.14

Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation (2013) 3.02

Medical treatment of peripheral arterial disease. JAMA (2006) 2.76

Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation (2013) 2.72

Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation (2004) 2.69

Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med (2004) 2.65

Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol (2012) 2.63

Aspirin resistance. Lancet (2006) 2.54

Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet (2009) 2.53

Management of antiphospholipid antibody syndrome: a systematic review. JAMA (2006) 2.47

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation (2010) 2.46

Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med (2006) 2.40

Venous thromboembolism: diagnosis and management of pulmonary embolism. Med J Aust (2005) 2.20

Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol (2012) 2.19

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation (2012) 2.18

Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07

Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation (2012) 1.91

The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. Eur Heart J (2012) 1.82

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol (2007) 1.75

Dabigatran etexilate: a new oral thrombin inhibitor. Circulation (2011) 1.66

Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J (2008) 1.65

Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation (2005) 1.63

Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood (2012) 1.59

New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.59

The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. Med J Aust (2008) 1.57

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a North American perspective: executive summary. Circ Cardiovasc Interv (2011) 1.56

Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med (2011) 1.56

Beyond unfractionated heparin and warfarin: current and future advances. Circulation (2007) 1.52

Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. Am Heart J (2010) 1.51

Translational success stories: development of direct thrombin inhibitors. Circ Res (2012) 1.49

Does acetyl salicylic acid (ASA) have a role in the prevention of venous thromboembolism? Br J Haematol (2009) 1.46

Methylenetetrahydrofolate reductase polymorphisms and homocysteine-lowering effect of vitamin therapy in Singaporean stroke patients. Stroke (2006) 1.46

Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting. Circ Cardiovasc Interv (2011) 1.45

Pexelizumab does not "complement" percutaneous coronary intervention in patients with ST-elevation myocardial infarction. JAMA (2007) 1.45

Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.34

Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med (2006) 1.34

Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. Nat Clin Pract Cardiovasc Med (2008) 1.33

Does this patient have pulmonary embolism? JAMA (2003) 1.30

Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol (2012) 1.23

A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J (2012) 1.22

Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost (2014) 1.22

Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation (2010) 1.20

Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol (2012) 1.18

Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke (2003) 1.16

Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation (2012) 1.14

Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events. Lancet Neurol (2010) 1.09

New oral anticoagulants in elderly patients. Best Pract Res Clin Haematol (2013) 1.08

Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can J Cardiol (2013) 1.05

Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med (2002) 1.04

The effect of blood storage duration on in-hospital mortality: a randomized controlled pilot feasibility trial. Transfusion (2012) 1.03

The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J (2012) 1.02

Homocysteine or renal impairment: which is the real cardiovascular risk factor? Arterioscler Thromb Vasc Biol (2008) 1.01

Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs (2006) 1.01

Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica (2003) 1.00

Association of atrial fibrillation with mortality and disability after ischemic stroke. Neurology (2013) 0.99

B vitamins and magnetic resonance imaging-detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy. Stroke (2012) 0.99

Peripheral arterial disease: prognostic significance and prevention of atherothrombotic complications. Med J Aust (2004) 0.97

The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J (2008) 0.97

Inherited thrombophilia and pregnancy associated venous thromboembolism. BMJ (2007) 0.96

Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes (2010) 0.96

Protein Z in ischemic stroke and its etiologic subtypes. Stroke (2003) 0.96

An electronic tool for venous thromboembolism prevention in medical and surgical patients. Haematologica (2006) 0.94

Warfarin in heart failure. N Engl J Med (2012) 0.93

Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation (2009) 0.90

Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation (2008) 0.90

Homocysteine and stroke. Lancet (2005) 0.89

Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis (2013) 0.89

Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial. J Thromb Thrombolysis (2012) 0.88

Cardiology patient page: Aspirin. Circulation (2012) 0.88

The aspirin controversy in primary prevention. Curr Opin Cardiol (2012) 0.88

Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke (2012) 0.88

Clinical usefulness of plasma homocysteine in vascular disease. Med J Aust (2004) 0.87

Preventing cardioembolic stroke in atrial fibrillation with dabigatran. Curr Neurol Neurosci Rep (2012) 0.87

Atrial fibrillation is associated with increased mortality: causation or association? Eur Heart J (2013) 0.87

Aspirin resistance. Thromb Res (2007) 0.86

Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. Eur Heart J (2011) 0.85

The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial. BMC Geriatr (2013) 0.85

Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol (2013) 0.85

The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion (2012) 0.85

Who is (still) getting HIT? Chest (2007) 0.85

A replacement for warfarin: the search continues. Circulation (2007) 0.85

Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. Thromb Res (2011) 0.84

Aspirin resistance. BMJ (2004) 0.84

New antithrombotic agents--insights from clinical trials. Nat Rev Cardiol (2010) 0.84

Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation? Stroke (2012) 0.84

Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial. Am Heart J (2009) 0.84

Venous thromboembolism: diagnosis and management of deep venous thrombosis. Med J Aust (2005) 0.83

Reply: regarding the effect of dabigatran plasma concentrations. J Am Coll Cardiol (2014) 0.83

Thromboprophylaxis practice patterns in two Western Australian teaching hospitals. Haematologica (2004) 0.83